

# Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

NCT02932150

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Gilead Sciences
Enrollment	150 participants

## Key Eligibility Criteria

---

### Inclusion (15)

- Males and non-pregnant, non-lactating females
- Weight at screening as follows:
- Cohort 1 = e 35 kg (e 77 lbs)
- Cohort 2 Group 1 = e 25 kg (e 55 lbs)
- Cohort 2 Group 2 = e 14 kg to < 25 kg (e 30 lbs to <55 lbs)

... and 10 more (see full listing online)

### Exclusion (12)

- Females who are pregnant or breastfeeding
- Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study.
- Coinfection with hepatitis C virus (HCV), HIV, or hepatitis D virus (HDV)
- Evidence of hepatocellular carcinoma (Note: if screening alpha-fetoprotein (AFP) is < 50 ng/mL no imaging study is needed; however, if the screening AFP is > 50 ng/mL an imaging study is required)
- Any history of, or current evidence of, clinical hepatic decompensation

... and 7 more (see full listing online)

## Locations (62 total)

---

Children's Hospital of Los Angeles, Los Angeles, California, United States  
Rady Childrens Hospital, San Diego, California, United States  
University of California, San Francisco (UCSF), San Francisco, California, United States  
... and 59 more locations

---

<https://clinicaltrials.gov/study/NCT02932150>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.